Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 238Cyclophosphamide 192Vincristine 164Doxorubicin 150Prednisone 126Methotrexate 80Cytarabine 79Etoposide 78Dexamethasone 72Radiotherapy 60Bendamustine Hydrochloride 58Mercaptopurine 46Lenalidomide 42pegaspargase 41Prednisolone 38Filgrastim 38ibrutinib 37fludarabine 36Bleomycin 36Daunorubicin 35obinutuzumab 34Asparaginase 33Leucovorin 29venetoclax 28Granulocyte Colony-Stimulating Factor 28Chlorambucil 27Calcium Dobesilate 27Gemcitabine 26Vinblastine 25Thioguanine 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × enzastaurin × Lymphoid × Clear all
NCT00332202 2018-09-10

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Eli Lilly and Company

Phase 3 Completed
758 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡